Innovation

Hsp90 Inhibitors

University of Kansas
posted on 10/03/2005

The molecules identified herein are designed to inhibit Hsp90 and thus prevent the conformational maturation of Hsp90 dependent proteins.

Suggested Uses

Inhibitors of Hsp90 have been shown to be active against several cancers and the molecules described herein may have similar potential to 17-allylaminogeldanamycin, which is currently in Phase I clinical trials for the treatment of cancer.

Innovation Details
 

Detailed Description

Hsp90 is a molecular chaperone responsible for folding denatured and nascent proteins. Numerous proteins required for cancerous growth are dependent on Hsp90 for their conformational maturation to a biologically active three-dimensional protein. Inhibition of Hsp90 results in the simultaneous inhibition of multiple protein targets. The molecules identified herein are designed to inhibit Hsp90 and thus prevent the conformational maturation of Hsp90 dependent proteins.

File Number: 2004 FY 10 

Other Information: *State of Development* The molecules described herein represent the first set of new lead compounds for the inhibition of Hsp90. Future studies will be required to determine whether these molecules can be further optimized and whether they behave similarly in cells/animals. Available for licensing.


IP Protection


License Online

This innovation currently is not available for online licensing. Please contact Aswini Betha at University of Kansas for more information.

request more info
People

Case Manager:

Icon_avatar Aswini Betha

Innovations (32)

Followed By

Follow this innovation



No one is following this innovation.

Organization
Profile
Related Tags

Find more innovations


February 11, 2009

3,941 members 11,891 innovations 107 organizations

Browse

Dr. Jörg Knäblein – Technology Scouting, Bayer Schering Pharma AG

"Through the iBridge Network, I was able to find a mouse model I was looking for. The collaboration available through the iBridge Network is crucial in driving innovation and I'll continue using it as a valued resource."  read more...